Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on invested capital (ROIC) is -46.16% as of the fiscal period ended Tuesday, June 30, 2026.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation.
Limited quarterly history available
ROIC needs at least three reported quarters before a meaningful chart is shown.
RETURN ON INVESTED CAPITAL (ROIC)
-46.16%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.53%
median of 573 covered companies
CURRENT VS SECTOR MEDIAN
-41.89%
vs the sector median at left
Eikon Therapeutics, Inc. Common Stock
Market Cap
$411.99M
Return on Invested Capital (ROIC)
-46.16%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$412.27M
Return on Invested Capital (ROIC)
-19.13%
TTM Avg
-11.02%
3Y Avg
-12.07%
5Y Avg
-13.96%
Market Cap
$408.32M
Return on Invested Capital (ROIC)
-36.54%
TTM Avg
-40.95%
3Y Avg
-100.88%
5Y Avg
-100.88%
Market Cap
$407.09M
Return on Invested Capital (ROIC)
-25.26%
TTM Avg
-29.12%
3Y Avg
-26.65%
5Y Avg
-26.65%
Market Cap
$406.54M
Return on Invested Capital (ROIC)
-89.93%
TTM Avg
-54.36%
3Y Avg
-39.52%
5Y Avg
-23.86%
Market Cap
$402.01M
Return on Invested Capital (ROIC)
-54.45%
TTM Avg
-31.52%
3Y Avg
-36.49%
5Y Avg
-36.90%
Market Cap
$425.86M
Return on Invested Capital (ROIC)
-48.61%
TTM Avg
-80.33%
3Y Avg
-62.04%
5Y Avg
-50.84%
Market Cap
$432.69M
Return on Invested Capital (ROIC)
-40.25%
TTM Avg
-30.86%
3Y Avg
-64.07%
5Y Avg
-59.14%
Market Cap
$437.27M
Return on Invested Capital (ROIC)
-2.86%
TTM Avg
-34.72%
3Y Avg
-61.44%
5Y Avg
-57.77%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Eikon Therapeutics, Inc. Common Stock (EIKN) | $411.99M | -46.16% | N/A | N/A | N/A |
| Myriad Genetics, Inc. (MYGN)vs › | $412.27M | -19.13% | -11.02% | -12.07% | -13.96% |
| Carlsmed, Inc. (CARL)vs › | $408.32M | -36.54% | -40.95% | -100.88% | -100.88% |
| Shoulder Innovations, Inc. (SI)vs › | $407.09M | -25.26% | -29.12% | -26.65% | -26.65% |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $406.54M | -89.93% | -54.36% | -39.52% | -23.86% |
| Neurogene Inc. (NGNE)vs › | $402.01M | -54.45% | -31.52% | -36.49% | -36.90% |
| Editas Medicine, Inc. (EDIT)vs › | $425.86M | -48.61% | -80.33% | -62.04% | -50.84% |
| Capricor Therapeutics, Inc. (CAPR)vs › | $432.69M | -40.25% | -30.86% | -64.07% | -59.14% |
| Assembly Biosciences, Inc. (ASMB)vs › | $437.27M | -2.86% | -34.72% | -61.44% | -57.77% |
| MapLight Therapeutics, Inc. (MPLT)vs › | $384.04M | -69.35% | -52.27% | -73.46% | -73.46% |
ROIC
-46.2%
ROE
-69.1%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | -46.16% |
